Celgene presents results of Iberdomide-Dexamethasone combination study
Category: #health  By Pankaj Singh  Date: 2019-06-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Celgene presents results of Iberdomide-Dexamethasone combination study

Celgene Corporation, a U.S.-based biotechnology company recently announced first clinical results evaluating CC-220 (Iberdomide) in combination with dexamethasone in patients with relapsed & refractory multiple myeloma from a Phase 1/2 study, cites source.

Reportedly, the results included preliminary safety & efficacy data from the study which aims to determine maximum tolerated dose and the recommended phase 2 dose of Iberdomide in combination with dexamethasone. Iberdomide is Celgene’s patented cereblon E3 ligase modulator compound with enhanced tumoricidal & immune stimulatory effects proven in preclinical studies. In the phase 1/2 study, approximately 300 participants are expected to enroll.

As per reliable sources, 66 patients at a median age of 65 received the Iberdomide and dexamethasone combination, in 8 incremental doses ranging from 0.3 mg-1.3 mg. Increasing Iberdomide doses were given on days 1 to 21 in along with dexamethasone on days 1, 8, 15 & 22 of each 28-day cycle. The patients had a median of 5 prior multiple myeloma treatments. The treatments could have included- proteasome inhibitors & daratumumab, stem cell transplant and immunomodulatory drugs including lenalidomide & pomalidomide.

Adverse events reported included peripheral sensory neuropathy (1.5%), pulmonary embolism (1.5%), thrombocytopenia (12%), anemia (24%), infection (26%) and neutropenia (29%). Treatment was discontinued by 6 patients due to adverse events. Out of 66 patients who received the combination, 59 were evaluable for response. The overall response rate was 32%, out of which 29% achieved a partial response and 2 patients achieved very good partial response.

Dr. Alise Reicin, President of Global Clinical Development, Celgene was reportedly quoted saying that the preliminary clinical activity & favorable safety data observed with the combination of Iberdomide & dexamethasone are encouraging, particularly in patients who experienced failed therapies, including patients who were refractory to pomalidomide or daratumumab & lenalidomide.

Patients who were refractory to immunomodulatory medications, that included lenalidomide & pomalidomide, had an overall response rate of 35% with 33% patients achieving partial response & 1 patient recorded very good partial response.

Source credits: https://ir.celgene.com/press-releases/press-release-details/2019/Celgene-Presents-Data-from-a-Phase-12-Clinical-Study-of-Iberdomide-in-Combination-with-Dexamethasone-in-Patients-with-Relapsed-and-Refractory-Multiple-Myeloma-at-ASCO-2019/default.aspx



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Amazon, NinjaCart in talks, retail firm to invest in fresh produce
Amazon, NinjaCart in talks, retail firm to invest in fresh produce
By Pankaj Singh

US-based tech giant looks enter one of the biggest untapped sectors

Amazon reportedly had meetings with Bengaluru-based fresh produce supply chain firm, NinjaCart, ...

Poshmark expands its retail business, ventures into home décor
Poshmark expands its retail business, ventures into home décor
By Pankaj Singh

The U.S.-based retail firm Poshmark has reportedly announced that it is expanding beyond its fashion market involving resale of clothes, bags, footwear and accessories to home decor.

Adverum Biotechnologies doses first Wet AMD patient in phase-1 trial

Adverum Biotechnologies doses first Wet AMD patient in phase-1 trial
By Pankaj Singh

The California-based Adverum Biotechnologies Inc., which caters to the unmet medical requirements in rare and ocular diseases, has announced that it dosed its first wet AMD patient in the second cohort of its OPTIC pha...